

## ASX Release

### **Anatara finalises draft protocol for a randomised controlled clinical trial in irritable bowel syndrome**

#### **Highlights**

- Anatara has met the projected milestone to finalise a draft protocol for a human clinical trial for its Gastrointestinal ReProgramming dietary supplement (GaRP)
- Meeting this milestone keeps Anatara on track to commence this human clinical trial 2Q 2020

BRISBANE & MELBOURNE, 20th December 2019: Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.

Anatara has met the projected milestone to finalise a draft protocol for a human clinical trial for GaRP and has commenced the process of selecting a clinical research organisation (CRO).

Anatara's CEO, Mr Steven Lydeamore said, "There is a major unmet medical need and significant market opportunity for an evidence-based dietary supplement for IBS. Meeting this milestone keeps Anatara on track to commence this human clinical trial 2Q 2020."

GaRP is being developed to specifically target two human gastrointestinal (GI) disorders, IBS and inflammatory bowel disease (IBD). IBS is the most common GI condition, affecting approximately 11% of the global population<sup>1</sup> while IBD affects an estimated five million people globally<sup>2</sup>.

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS<sup>3</sup> and IBD<sup>4</sup> patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and over-the-counter (OTC) digestive remedies in the US alone was US\$8 billion<sup>5,6</sup>.

#### **What is the aim of Anatara's GaRP dietary supplement?**

GaRP is a natural daily supplement that provides a unique and proprietary combination of clinically studied ingredients to deliver a holistic approach to gut health.

GaRP was specifically developed to improve and maintain gastrointestinal health and assist IBD and IBS patients manage their disease and the associated symptoms. It achieves this by:

- Restoring balance to the gut microbiome, which can improve digestive function and boost the immune system;
- Reducing gastrointestinal inflammation, delivering natural digestive support and providing ongoing gastrointestinal aid to help reduce digestive discomfort, better digest food and improve nutrient absorption;
- Promoting and supporting mucosal healing which in turn protects the lining in the gut;
- Restoring intestinal epithelial barrier integrity.



**For more information please contact:**

<b>General inquiries</b>	
<p>Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com</p>	<p>Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com</p>

<sup>1</sup> Clinical Gastroenterology and Hepatology 2012: 10, 712-721.

<sup>2</sup> Crohn's and Colitis Australia.

<sup>3</sup> Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.

<sup>4</sup> Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712

<sup>5</sup> Mintel's 2018 Digestive Health U.S., July 2019.

<sup>6</sup> 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

**About Anantara Lifesciences Ltd**

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

**Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

